Edwards Lifesciences CorpEW
Edwards Lifesciences Corp Financial Overview 2020–2024
Edwards Lifesciences executed a decisive strategic pivot, selling its Critical Care business for $4.2 billion to sharpen its focus on structural heart disease. This move transforms the company into a more specialized innovator, funded by a massive cash infusion. The strategy is clear: double down on high-growth markets by shedding a legacy unit and immediately reinvesting in new therapies, evidenced by the $798.8 million acquisition of heart failure specialist Endotronix in 2024. This aggressive portfolio reshaping makes the company a pure-play bet on advanced cardiovascular technology.
This focused approach builds on a consistent growth record. Net sales from the refocused business grew from $4.386 billion in FY2020 to $5.4 billion in FY2024, anchored by the core Transcatheter Aortic Valve Replacement (TAVR) franchise. The real acceleration is coming from newer platforms; the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment saw sales jump an explosive 75.2% in the first quarter of 2024. The company consistently fuels this pipeline with heavy spending, dedicating 19% of sales to research and development in FY2024, while also returning $1.2 billion to shareholders via stock buybacks that year.
Recent Developments (Q2 and Q3 2025)
Net sales growth accelerated through mid-2025, culminating in a 14.7% year-over-year increase to $1.55 billion in Q3 2025. The Transcatheter Mitral and Tricuspid Therapies (TMTT) division continued its rapid expansion, with sales surging 59.3% in the third quarter. However, bottom-line results were pressured by significant one-time costs, including $90.4 million in litigation expenses and a $40.0 million intangible asset impairment during Q3. The company also announced its CFO will transition from his role by mid-2026.
The bull case is that powerful top-line momentum from new product adoption will overcome temporary margin compression. Conversely, the bear case highlights that escalating litigation costs and repeated impairment charges may continue to erode profitability despite strong sales. The stock traded at a modest 11.9x earnings as of the Q3 2025 report date, suggesting the market is weighing these execution risks against the growth story.
What to watch: the ongoing IRS transfer pricing dispute; the CFO succession plan
Rev
$5.44B
FY2024
NI
$4.17B
FY2024
EPS
$6.98
FY2024
OCF
$542.3M
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
Edwards Lifesciences Corp 8-K Report, Financial Results (Feb 10, 2026)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on February 10, 2026, to announce its financial results for the fourth quarter of 2025. While the 8-K itself is brief and primarily serves to incorporate the details from a furnished press release (Exhibit 99.1), the core information pertains to the company's performance in the latest reported quarter. Investors should review the accompanying press release for specific figures on revenue, profitability, and any forward-looking guidance provided by the company.
Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Jan 12, 2026)
Edwards Lifesciences Corporation (EW) announced on January 11, 2026, that its proposed acquisition of JenaValve Technology, Inc. has been blocked by a preliminary injunction granted by the U.S. District Court for the District of Columbia at the request of the U.S. Federal Trade Commission (FTC). Consequently, the transaction will not proceed as planned. This development is a significant setback for Edwards Lifesciences' strategic growth initiatives and integration plans that hinged on the acquisition of JenaValve. Investors should focus on the implications of this failed acquisition, including potential impacts on future revenue streams, market positioning, and the company's capital allocation strategy. While the financial terms of the deal and any termination fees are not detailed in this 8-K, this event signifies a need for management to reassess its inorganic growth strategy and potentially seek alternative avenues for market expansion or product portfolio enhancement. The company's stock performance may be influenced by market reaction to this news and any subsequent management commentary.
Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 30, 2025)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on October 30, 2025, to disclose its financial results for the third quarter of 2025. The report primarily references a press release, dated October 30, 2025, which contains the detailed financial outcomes for the period. Investors should refer to this press release (Exhibit 99.1) for comprehensive information regarding the company's performance, including revenue, profitability, and any key operational metrics. This filing serves as notification of these results and does not represent new financial statements being filed directly within the 8-K. The furnished information under Item 2.02, including the press release, is not considered 'filed' for the purposes of the Securities Exchange Act of 1934, meaning the company retains protection against potential liabilities associated with such information until officially filed in subsequent reports. Investors are encouraged to review the press release for a full understanding of the company's third-quarter performance.
Edwards Lifesciences Corp 8-K Report, Executive Changes (Oct 30, 2025)
Edwards Lifesciences Corporation (EW) announced a significant leadership change via an 8-K filing on October 30, 2025. Chief Financial Officer (CFO) Scott Ullem has informed the company of his decision to transition out of his role by mid-2026. This development triggers an active search for a successor to lead the company's financial strategy. While the departure is planned for mid-2026, the immediate focus for investors is the initiation of the CFO selection process. This transition, though not immediate, is a key event that warrants attention as the company navigates its financial future. Investors will be keen to understand the timeline for appointing a new CFO and the potential impact on the company's financial management and strategic direction.
Edwards Lifesciences Corp 8-K Report, Corporate Update (Aug 19, 2025)
Edwards Lifesciences Corporation (EW) has announced its entry into an accelerated share repurchase (ASR) agreement, as detailed in an 8-K filing dated August 19, 2025. This strategic move indicates the company's commitment to returning capital to shareholders and reflects management's confidence in the company's financial health and future prospects. Investors should note that ASR agreements typically involve repurchasing a significant amount of stock in a short period, which can positively impact earnings per share and signal a belief by the company that its stock is undervalued. The press release filed as Exhibit 99.1 provides further details on the terms and expected impact of this repurchase program.
View all 8-K filings →